Publications by authors named "Fernando Monteiro"

Claim this Profile
T
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study).
Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, Hana Studentova, Ondrej Fiala, Fernando Sabino Marques Monteiro

Int J Cancer· March 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thermoresponsive nanoparticles for targeted and controlled delivery of doxorubicin in triple negative breast cancer: a 2D and 3D in vitro evaluation.
Tiago P Ribeiro, Francisca L Gomes, Rui Vilarinho, Christiane Salgado, Maria Cristina L Martins, Fernando J Monteiro

Drug Deliv Transl Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".
Javier Molina-Cerrillo, Giandomenico Roviello, Ondrej Fiala, Tarek Taha, Sebastiano Buti, Fernando Sabino Marques Monteiro

Int J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis.
Elsa Vitale, Alessandro Rizzo, Lorenza Maistrello, Omar Cauli, Oronzo Brunetti, Fernando Sabino Marques Monteiro

Drug Des Devel Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2 project.
Alessandro Rizzo, Zin W Myint, Francesco Ciccimarra, Anca Zgura, Marc R Matrana, Fernando Sabino Marques Monteiro

Clin Exp Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy in biliary tract cancer: effective but not enough?
Alessandro Rizzo, Enes Erul, Deniz Can Guven, Taha Koray Sahin, Fernando Sabino Marques Monteiro

Expert Rev Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.
Ray Manneh Kopp, Francesco Massari, Enrique Grande, Timothy J Schieber, Yüksel Ürün, Fernando Sabino Marques Monteiro

Cancer Immunol Immunother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Fernando Cotait Maluf, Karine Trindade, Daniel Preto, et al. Pembrolizumab plus Platinum-based Chemotherapy for Patients with Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2025.3266.
Fernando Sabino Marques Monteiro, Matteo Santoni, Philippe E Spiess

Eur Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.
Renate Pichler, Gerald Klinglmair, Kirstin Binz, Enrique Grande, Alina Pirshtuk, Fernando Sabino Marques Monteiro

Clin Exp Metastasis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.
Philipp Mandel, Daniel Groener, Giulia Follacchio, Yüksel Ürün, Maria T Bourlon, Fernando Sabino Marques Monteiro

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, Enrique Grande, Maria T Bourlon, Fernando Sabino Marques Monteiro

JCO Glob Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.
Alessandro Rizzo, Anas Zayed, Elsa Vitale, Sebastiano Buti, Hideki Takeshita, Fernando Sabino Marques Monteiro

Clin Exp Metastasis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid nano-scaffolds loaded with resveratrol and Omega-3 fatty Acids: An innovative antimicrobial strategy against biofilm.
Ana Beatriz V Pereira, Mariana S Terroso, Hugo Gonçalves, José Catita, Daniela Santos, Fernando J Monteiro

Int J Pharm· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, diversity and risk factors of gastrointestinal parasites in dogs housed at official shelters across Portugal.
Patrícia Lopes, Jacinto Gomes, João Lozano, Mariana Louro, Luís Madeira de Carvalho, Fernando Monteiro

Vet Parasitol Reg Stud Reports· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular characterization of Strongylida infecting goats and sheep in northeastern Brazil using cytochrome-c oxidase subunit I partial sequencing.
Kerla J L Monteiro, Deiviane A Calegar, Beatriz Coronato-Nunes, Jessica P Santos, Elis Regina C Dos Reis, Fernando Araújo Monteiro

Vet Parasitol Reg Stud Reports· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.
Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T Bourlon, Fernando Sabino Marques Monteiro

Cancer Immunol Immunother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2 study.
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, Alfonso Gómez de Liaño, Wataru Fukuokaya, Fernando Sabino Marques Monteiro

Clin Exp Metastasis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.
Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Fernando Sabino Marques Monteiro

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Fernando Sabino Marques Monteiro

Cancer Immunol Immunother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Veronica Mollica, Andrey Soares, Oronzo Brunetti

Clin Exp Metastasis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Veronica Mollica, Oronzo Brunetti, Elsa Vitale

Clin Exp Metastasis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiogenesis Dynamics: A Computational Model of Intravascular Flow Within a Structural Adaptive Vascular Network.
Sahar Jafari Nivlouei, Ana Guerra, Jorge Belinha, Naside Mangir, Sheila MacNeil, Fernando Jorge Monteiro

Biomedicines· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2 Study.
Ondřej Fiala, Francesco Massari, Umberto Basso, Patrizia Giannatempo, Enrique Grande, Fernando Sabino Marques Monteiro

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries.
Fernando Sabino Marques Monteiro, Andre Deeke Sasse, Denizar Vianna Araujo, Rana R McKay, Karine Martins da Trindade

JCO Glob Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis.
Elsa Vitale, Alessandro Rizzo, Lorenza Maistrello, Deniz Can Guven, Raffaella Massafra, Fernando Sabino Marques Monteiro

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis